These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 33911107)
21. In vitro activity of ceftazidime-avibactam and comparators against Enterobacterales and Pseudomonas aeruginosa isolates from Central Europe and Israel, 2014-2017 and 2018. Kristóf K; Adámková V; Adler A; Gospodarek-Komkowska E; Rafila A; Billová S; Możejko-Pastewka B; Kiss F Diagn Microbiol Infect Dis; 2021 Sep; 101(1):115420. PubMed ID: 34091111 [TBL] [Abstract][Full Text] [Related]
23. Performance of Ceftolozane-Tazobactam Etest, MIC Test Strips, and Disk Diffusion Compared to Reference Broth Microdilution for β-Lactam-Resistant Pseudomonas aeruginosa Isolates. Humphries RM; Hindler JA; Magnano P; Wong-Beringer A; Tibbetts R; Miller SA J Clin Microbiol; 2018 Mar; 56(3):. PubMed ID: 29212704 [TBL] [Abstract][Full Text] [Related]
24. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States. Sader HS; Huband MD; Castanheira M; Flamm RK Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069652 [No Abstract] [Full Text] [Related]
25. Assessment of 30/20-Microgram Disk Content versus MIC Results for Ceftazidime-Avibactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa. Sader HS; Rhomberg PR; Huband MD; Critchley IA; Stone GG; Flamm RK; Jones RN J Clin Microbiol; 2018 Jun; 56(6):. PubMed ID: 29563198 [TBL] [Abstract][Full Text] [Related]
26. In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: A two-centre study. Mirza HC; Hortaç E; Koçak AA; Demirkaya MH; Yayla B; Güçlü AÜ; Başustaoğlu A J Glob Antimicrob Resist; 2020 Mar; 20():334-338. PubMed ID: 31568882 [TBL] [Abstract][Full Text] [Related]
27. Multicenter Evaluation of the New Etest Gradient Diffusion Method for Piperacillin-Tazobactam Susceptibility Testing of García-Fernández S; Bala Y; Armstrong T; García-Castillo M; Burnham CA; Wallace MA; Hardy D; Zambardi G; Cantón R J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31597745 [TBL] [Abstract][Full Text] [Related]
28. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia. Henderson A; Tan E; McCarthy KL; Paterson DL Pathology; 2018 Dec; 50(7):748-752. PubMed ID: 30392710 [TBL] [Abstract][Full Text] [Related]
36. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the Yin D; Wu S; Yang Y; Shi Q; Dong D; Zhu D; Hu F; Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30617091 [TBL] [Abstract][Full Text] [Related]
37. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015. Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073 [TBL] [Abstract][Full Text] [Related]
38. In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012-15. Kazmierczak KM; de Jonge BLM; Stone GG; Sahm DF J Antimicrob Chemother; 2018 Oct; 73(10):2777-2781. PubMed ID: 30010951 [TBL] [Abstract][Full Text] [Related]
39. Susceptibility of MDR Pseudomonas aeruginosa to ceftolozane/tazobactam and comparison of different susceptibility testing methods. Schaumburg F; Bletz S; Mellmann A; Becker K; Idelevich EA J Antimicrob Chemother; 2017 Nov; 72(11):3079-3084. PubMed ID: 28961968 [TBL] [Abstract][Full Text] [Related]
40. Antimicrobial susceptibility of multidrug-resistant Pseudomonas aeruginosa isolated from drinking water and hospitalized patients in Jordan. Tarazi YH; Abu-Basha E; Ismail ZB; Al-Jawasreh SI Acta Trop; 2021 May; 217():105859. PubMed ID: 33582141 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]